Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Cantor Fitzgerald
Moodys
Fish and Richardson
Covington
Julphar
Citi
Chinese Patent Office
Cerilliant

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,233,118

« Back to Dashboard

Summary for Patent: 9,233,118
Title:Treatment of papulopustular rosacea with ivermectin
Abstract: Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.
Inventor(s): Jacovella; Jean (Antibes, FR), Chappuis; Jean-Paul (Valbonne, FR), Kaoukhov; Alexandre (Newport Beach, CA), Graeber; Michael (Lawrenceville, NJ), Poncet; Michel (Mougins, FR), Briantais; Philippe (Antibes, FR), Salin; Laurence (La Roquette sur Siagne, FR)
Assignee: Galderma S.A. (Cham, CH)
Application Number:14/209,958
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 9,233,118

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp SOOLANTRA ivermectin CREAM;TOPICAL 206255-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,233,118

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,782,425 Treatment of papulopustular rosacea with ivermectin ➤ Sign Up
9,089,587 Treatment of papulopustular rosacea with ivermectin ➤ Sign Up
9,233,117 Treatment of inflammatory lesions of rosacea with ivermectin ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Fuji
Harvard Business School
Federal Trade Commission
Cerilliant
QuintilesIMS
McKesson
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.